Biocytogen Grants Licence for RenNano Platform to Taisho Pharmaceutical
Biocytogen licenses its RenNano platform to Taisho Pharmaceutical to advance fully human heavy chain-only antibody discovery, supporting in-vivo screening and downstream research.
Dr Yuelei Shen | 31/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy